Cytokine-modified VSV is attenuated for neural pathology, but is both highly immunogenic and oncolytic

References

• Johnson KM, Vogel JE, Peralta PH. Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV). Am J Trop Med Hyg. 1966;15:244–246.
   PubMed Web of Science ®Google Scholar
• Fields BN, Hawkins K. Human infection with the virus of vesicular stomatitis during an epizootic. N Engl J Med. 1967;277:989–994.
   PubMed Web of Science ®Google Scholar
• Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol. 2000;81:2341–2364.
   PubMed Web of Science ®Google Scholar
• Katze MG, He Y, Gale M, Jr. Viruses and interferon: a fight for supremacy. Nat Rev Immunol. 2002;2:675–687.
   PubMed Web of Science ®Google Scholar
• Belkowski LS, Sen GC. Inhibition of vesicular stomatitis viral mRNA synthesis by interferons. J Virol. 1987;61:653–660.
   Web of Science ®Google Scholar
• Glodowski DR, Petersen JM, Dahlberg JE. Nuclear localization of the Matrix protein of VSV, an inhibitor of nucleocytoplasmic transport. Mol Biol Cell. 2001;12:107a–107a.
   Web of Science ®Google Scholar
• Petersen JM, Her LS, Varvel V, Lund E, Dahlberg JE. The matrix protein of vesicular stomatitis virus inhibits nucleocytoplasmic transport when it is in the nucleus and associated with nuclear pore complexes. Mol Cell Biol. 2000;20:8590–8601.
   PubMed Web of Science ®Google Scholar
• Ahmed M, McKenzie MO, Puckett S, Hojnacki M, Poliquin L, Lyles DS. Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J Virol. 2003;77:4646–4657.
   Web of Science ®Google Scholar
• Balachandran S, Barber GN. Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell. 2004;5:51–65.
   PubMed Web of Science ®Google Scholar
• Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000;6:821–825.
   PubMed Web of Science ®Google Scholar
• Barber GN. Vesicular stomatitis virus as an oncolytic vector. Viral Immunol. 2004;17:516–527.
   PubMed Web of Science ®Google Scholar
• Connor JH, Naczki C, Koumenis C, Lyles DS. Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo. J Virol. 2004;78:8960–8970.
   Web of Science ®Google Scholar
• Ahmed M, Cramer SD, Lyles DS. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology. 2004;330:34–49.
   PubMed Web of Science ®Google Scholar
• Pearce AF, Lyles DS. Vesicular stomatitis virus induces apoptosis primarily through Bak rather than Bax by inactivating Mcl-1 and Bcl-XL. J Virol. 2009;83:9102–9112.
   Web of Science ®Google Scholar
• Duntsch CD, Zhou Q, Jayakar HR, et al. Recombinant vesicular stomatitis virus vectors as oncolytic agents in the treatment of high-grade gliomas in an organotypic brain tissue slice-glioma coculture model. J Neurosurg. 2004;100:1049–1059.
   Web of Science ®Google Scholar
• Huneycutt BS, Plakhov IV, Shusterman Z, et al. Distribution of vesicular stomatitis virus proteins in the brains of BALB/c mice following intranasal inoculation: an immunohistochemical analysis. Brain Res. 1994;635:81–95.
   PubMed Web of Science ®Google Scholar
• Reiss CS, Aoki C. Vesicular Stomatitis-Virus – Immune Recognition, Responsiveness, and Pathogenesis of Infection in Mice. Rev Med Virol. 1994;4:129–140.
   Web of Science ®Google Scholar
• Reiss CS. RNA viruses: host gene responses to infections. Hackensack, NJ: World Scientific, 2009; Chapter 10.
   Google Scholar
• Steinhoff U, Muller U, Schertler A, Hengartner H, Aguet M, Zinkernagel RM. Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice. J Virol. 1995;69:2153–2158.
   PubMed Web of Science ®Google Scholar
• Gupta SC, Hengartner H, Zinkernagel RM. Primary antibody responses to a well-defined and unique hapten are not enhanced by preimmunization with carrier: analysis in a viral model. Proc Natl Acad Sci US A. 1986;83:2604–2608.
   Web of Science ®Google Scholar
• Muller U, Steinhoff U, Reis LFL, et al. Functional-role of type-I and type-II interferons in antiviral defense. Science. 1994;264:1918–1921.
   PubMed Web of Science ®Google Scholar
• van den Broek MF, Muller U, Huang S, Aguet M, Zinkernagel RM. Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J Virol. 1995;69:4792–4796.
   PubMed Web of Science ®Google Scholar
• Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell. 1996;84:443–450.
   PubMed Web of Science ®Google Scholar
• Ebert O, Harbaran S, Shinozaki K, Woo SL. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther. 2005;12:350–358.
   PubMed Web of Science ®Google Scholar
• Forger JM, Bronson RT, Huang AS, Reiss CS. Murine infection by vesicular stomatitis-virus – Initial characterization of the H-2d system. J Virol. 1991;65:4950–4958.
   PubMed Web of Science ®Google Scholar
• Bi ZB, Barna M, Komatsu T, Reiss CS. Vesicular stomatitis-virus infection of the central-nervous-system activates both innate and acquired immunity. J Virol. 1995;69:6466–6472.
   PubMed Web of Science ®Google Scholar
• Johnson JE, Nasar F, Coleman JW, et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology. 2007;360:36–49.
   PubMed Web of Science ®Google Scholar
• Chen N, Restivo A, Reiss CS. Leukotrienes play protective roles early during experimental VSV encephalitis. J Neuroimmunol. 2001;120:94–102.
   PubMed Web of Science ®Google Scholar
• Reiss CS, Chesler DA, Hodges J, Ireland DD, Chen N. Innate immune responses in viral encephalitis. Curr Top Microbiol Immunol. 2002;265:63–94.
   Web of Science ®Google Scholar
• Christian AY, Barna M, Bi ZB, Reiss CS. Host immune response to vesicular stomatitis virus infection of the central nervous system in C57BL/6 mice. Viral Immunol. 1996;9:195–205.
   Web of Science ®Google Scholar
• Diebold SS, Kaisho T, Hemmi H, Akira S, Sousa CRE. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004;303:1529–1531.
   PubMed Web of Science ®Google Scholar
• Trottier MD, Lyles DS, Reiss CS. Peripheral, but not central nervous system, type I interferon expression in mice in response to intranasal vesicular stomatitis virus infection. J Neurovirol. 2007;13:433–445.
   Web of Science ®Google Scholar
• Christian AY, Barna M, Bi Z, Reiss CS. Host immune response to vesicular stomatitis virus infection of the central nervous system in C57BL/6 mice. Viral Immunol. 1996;9:195–205.
   Web of Science ®Google Scholar
• Bartido SM, Zier K. T-cell responses to multiple antigens presented by RNA-transfected APCs: a possible immunomonitoring tool. Cancer Immunol Immunother. 2004;53:100–109.
   Web of Science ®Google Scholar
• Browning MJ, Huang AS, Reiss CS. Cytolytic T lymphocytes from the BALB/c-H-2dm2 mouse recognize the vesicular stomatitis virus glycoprotein and are restricted by class II MHC antigens. J Immunol. 1990;145:985–994.
   Web of Science ®Google Scholar
• Browning M, Reiss CS, Huang AS. The soluble viral glycoprotein of vesicular stomatitis virus efficiently sensitizes target cells for lysis by CD4+ T lymphocytes. J Virol. 1990;64:3810–3816.
   Web of Science ®Google Scholar
• Browning MJ, Huneycutt BS, Huang AS, Reiss CS. Replication-defective viruses modulate immune responses. J Immunol. 1991;147:2685–2691.
   Web of Science ®Google Scholar
• Reiss CS, Gapud CP, Keil W. Newly synthesized class II MHC chains are required for VSV G presentation to CTL clones. Cell Immunol. 1992;139:229–238.
   Web of Science ®Google Scholar
• Charan S, Hengartner H, Zinkernagel RM. Antibodies against the two serotypes of vesicular stomatitis virus measured by enzyme-linked immunosorbent assay: immunodominance of serotype-specific determinants and induction of asymmetrically cross-reactive antibodies. J Virol. 1987;61:2509–2514.
   Web of Science ®Google Scholar
• Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168:5699–5708.
   PubMed Web of Science ®Google Scholar
• Bastos KRB, Marinho CRF, Barboza R, Russo M, Alvarez JM, Lima MRD. What kind of message does IL-12/IL-23 bring to macrophages and dendritic cells? Microbes Infect. 2004;6:630–636.
   PubMed Web of Science ®Google Scholar
• Ivanov, II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126:1121–1133.
   PubMed Web of Science ®Google Scholar
• Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715–725.
   PubMed Web of Science ®Google Scholar
• McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 2006;27:17–23.
   PubMed Web of Science ®Google Scholar
• Farago B, Magyari L, Safrany E, et al. Functional variants of interleukin-23 receptor gene confer risk for rheumatoid arthritis but not for systemic sclerosis. Ann Rheum Dis. 2008;67:248–250.
   PubMed Web of Science ®Google Scholar
• Becher B, Durell BG, Noelle RJ. IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J Clin Invest. 2003;112:1186–1191.
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235–238.
   PubMed Web of Science ®Google Scholar
• Kim HR, Cho ML, Kim KW, et al. Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase-, NF-kappaB- and p38 MAPK-dependent signalling pathways. Rheumatol (Oxf). 2007;46:57–64.
   PubMed Web of Science ®Google Scholar
• Kaiga T, Sato M, Kaneda H, Iwakura Y, Takayama T, Tahara H. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J Immunol. 2007;178:7571–7580.
   PubMed Web of Science ®Google Scholar
• Tahara H, Lotze MT. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther. 1995;2:96–106.
   PubMed Web of Science ®Google Scholar
• Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol. 1994;153:1697–1706.
   PubMed Web of Science ®Google Scholar
• Lo CH, Lee SC, Wu PY, et al. Antitumor and antimetastatic activity of IL-23. J Immunol. 2003;171:600–607.
   PubMed Web of Science ®Google Scholar
• Cohen J. IL-12 deaths: explanation and a puzzle. Science. 1995;270:908.
   PubMed Web of Science ®Google Scholar
• Car BD, Eng VM, Lipman JM, Anderson TD. The toxicology of interleukin-12: a review. Toxicol Pathol. 1999;27:58–63.
   PubMed Web of Science ®Google Scholar
• Overwijk WW, de Visser KE, Tirion FH, et al. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol. 2006;176:5213–5222.
   PubMed Web of Science ®Google Scholar
• Hao JS, Shan BE. Immune enhancement and anti-tumour activity of IL-23. Cancer Immunol Immunother. 2006;55:1426–1431.
   PubMed Web of Science ®Google Scholar
• Liu L, Shan B, Feng Y. Antitumor effects and immunoregulation mechanisms of IL-23 gene in mouse mammary cancer mediated by retrovirus. Cell Immunol. 2009;258:181–187.
   Web of Science ®Google Scholar
• Belladonna ML, Renauld JC, Bianchi R, et al. IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J Immunol. 2002;168:5448–5454.
   PubMed Web of Science ®Google Scholar
• Lawson ND, Stillman EA, Whitt MA, Rose JK. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A. 1995;92:4477–4481.
   PubMed Web of Science ®Google Scholar
• Shin EJ, Wanna GB, Choi B, et al. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma. Laryngoscope. 2007;117:210–214.
   PubMed Web of Science ®Google Scholar
• Reiss CS, Chen SS, Huang AS, Doherty R. VSV G protein induces murine cytolytic T lymphocytes. Microb Pathog. 1986;1:261–267.
   Web of Science ®Google Scholar
• Biron CA. Activation and function of natural killer cell responses during viral infections. Curr Opin Immunol. 1997;9:24–34.
   PubMed Web of Science ®Google Scholar
• Wright SC, Bonavida B. YAC-1 variant clones selected for resistance to natural killer cytotoxic factors are also resistant to natural killer cell-mediated cytotoxicity. Proc Natl Acad Sci U S A. 1983;80:1688–1692.
   Google Scholar
• Lundh B, Kristensson K, Norrby E. Selective infections of olfactory and respiratory epithelium by vesicular stomatitis and sendai viruses. Neuropathol Appl Neurobiol. 1987;13:111–122.
   Web of Science ®Google Scholar
• Plakhov IV, Arlund EE, Aoki C, Reiss CS. The earlie st events in vesicular stomatitis virus infection of the murine olfactory neuroepithelium and entry of the central nervous system. Virology. 1995;209:257–262.
   PubMed Web of Science ®Google Scholar
• Bi ZB, Reiss CS. Inhibition of vesicular stomatitis-virus (Vsv) infection by nitric oxide. J Cell Biochem. 1995:305–305.
   Web of Science ®Google Scholar
• Komatsu T, Bi Z, Reiss CS. Interferon-gamma induced type I nitric oxide synthase activity inhibits viral replication in neurons. J Neuroimmunol. 1996;68:101–108.
   Web of Science ®Google Scholar
• Barna M, Komatsu T, Reiss CS. Activation of type III nitric oxide synthase in astrocytes following a neurotropic viral infection. Virology. 1996;223:331–343.
   PubMed Web of Science ®Google Scholar
• Bi Z, Quandt P, Komatsu T, Barna M, Reiss CS. IL-12 promotes enhanced recovery from vesicular stomatitis virus infection of the central nervous system. J Immunol. 1995;155:5684–5689.
   Web of Science ®Google Scholar
• Reiss CS, Komatsu T, Barna M, Bi Z. Interleukin-12 promotes enhanced recovery from viral infection of neurons in the central nervous system. Ann N YAcad Sci. 1996;795:257–265.
   Web of Science ®Google Scholar
• Komatsu T, Barna M, Reiss CS. Interleukin-12 promotes recovery from viral encephalitis. Viral Immunol. 1997;10:35–47.
   Web of Science ®Google Scholar
• Kopecky SA, Willingham MC, Lyles DS. Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus. J Virol. 2001;75:12169–12181.
   Web of Science ®Google Scholar
• Balachandran S, Porosnicu M, Barber GN. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or Myc function and involves the induction of apoptosis. J Virol. 2001;75:3474–3479.
   PubMed Web of Science ®Google Scholar
• Huszthy PC, Giroglou T, Tsinkalovsky O, et al. Remission of invasive, cancer stem-like glioblastoma xenografts using lentiviral vector-mediated suicide gene therapy. PLoS One. 2009;4:e6314.
   PubMed Web of Science ®Google Scholar
• Huang TG, Ebert O, Shinozaki K, Garcia-Sastre A, Woo SLC. Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice. Mol Ther. 2003;8:434–440.
   PubMed Web of Science ®Google Scholar
• Shi W, Tang QQ, Chen XC, et al. Antitumor and antimetastatic activities of vesicular stomatitis virus matrix protein in a murine model of breast cancer. J Mol Med. 2009;87:493–506.
   Web of Science ®Google Scholar
• Gao Y, Whitaker-Dowling P, Griffin JA, Barmada MA, Bergman I. Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors. Cancer Gene Ther. 2009;16:44–52.
   Web of Science ®Google Scholar
• Tumilasci VF, Oliere S, Nguyen TLA, Shamy A, Bell J, Hiscott J. Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis. J Virol. 2008;82:8487–8499.
   Web of Science ®Google Scholar
• Cesaire R, Oliere S, Sharif-Askari E, et al. Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia. Oncogene. 2006;25:349–358.
   Web of Science ®Google Scholar
• Shinozaki K, Ebert O, Woo SLC. Treatment of multi-focal colorectal carcinoma metastatic to the liver of immune-competent and syngeneic rats by hepatic artery infusion of oncolytic vesicular stomatitis virus. Int J Cancer. 2005;114:659–664.
   Web of Science ®Google Scholar
• Shinozaki K, Ebert O, Kournioti C, Tai YS, Woo SLC. Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus. Mol Ther. 2004;9:368–376.
   Web of Science ®Google Scholar
• Altomonte J, Braren R, Schulz S, et al. Synergistic Antitumor Effects of Transarterial Viroembolization for Multifocal Hepatocellular Carcinoma in Rats. Hepatology. 2008;48:1864–1873.
   Web of Science ®Google Scholar
• Feng Y, He G, Wu Y, Wen Y. Effect of apoptosis of vesicular stomatitis virus on tumor cells of nasopharyngeal carcinoma in vivo. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2008;22:995–997.
   Google Scholar
• Hadaschik BA, Zhang K, So AI, et al. Oncolytic vesicular stomatitis viruses as intravesical agents against non-muscle-invasive bladder cancer. Urologe. 2008;47:1145–1151.
   Web of Science ®Google Scholar
• Hadaschik BA, Zhang K, So AI, et al. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer. Cancer Res. 2008;68:4506–4510.
   PubMed Web of Science ®Google Scholar
• Letchworth GJ, Rodriguez LL, Del cbarrera J. Vesicular stomatitis. Vet J. 1999;157:239–260.
   PubMed Web of Science ®Google Scholar
• Schnell MJ, Buonocore L, Whitt MA, Rose JK. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J Virol. 1996;70:2318–2323.
   PubMed Web of Science ®Google Scholar
• Roberts A, Kretzschmar E, Perkins AS, et al. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol. 1998;72:4704–4711.
   PubMed Web of Science ®Google Scholar
• Schlereth B, Rose JK, Buonocore L, ter Meulen V, Niewiesk S. Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies. J Virol. 2000;74:4652–4657.
   PubMed Web of Science ®Google Scholar
• Kahn JS, Schnell MJ, Buonocore L, Rose JK. Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion. Virology. 1999;254:81–91.
   PubMed Web of Science ®Google Scholar
• Chen NN, Reiss CS. Innate immunity in viral encephalitis: Role of C5. Viral Immunol. 2002;15:365–372.
   PubMed Web of Science ®Google Scholar
• Chesler DA, Reiss CS. The role of IFN-gamma in immune responses to viral infections of the central nervous system. Cytokine Growth Factor Rev. 2002;13:441–454.
   PubMed Web of Science ®Google Scholar
• Ireland DDC, Reiss CS. Gene expression contributing to recruitment of circulating cells in response to vesicular stomatitis virus infection of the CNS. Viral Immunol. 2006;19:536–545.
   Web of Science ®Google Scholar
• Ireland DD, Bang T, Komatsu T, Reiss CS. Delayed administration of interleukin-12 is efficacious in promoting recovery from lethal viral encephalitis. Viral Immunol. 1999;12:35–40.
   PubMed Web of Science ®Google Scholar
• Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin- 12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003;421:744–748.
   PubMed Web of Science ®Google Scholar
• Yuan X, Hu J, Belladonna ML, Black KL, Yu JS. Interleukin-23- expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma. Cancer Res. 2006;66:2630–2638.
   PubMed Web of Science ®Google Scholar
• Munson AE, Phillips KE. Natural killer cells and immunotoxicology. Methods Mol Biol. 2000;121:359–365.
   Google Scholar
• Min B, Foucras G, Meier-Schellersheim M, Paul WE. Spontaneous proliferation, a response of naive CD4 T cells determined by the diversity of the memory cell repertoire. Proc Natl Acad Sci U S A. 2004;101:3874–3879.
   PubMed Web of Science ®Google Scholar
• Roberts A, Buonocore L, Price R, Forman J, Rose JK. Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol. 1999;73:3723–3732.
   PubMed Web of Science ®Google Scholar
• Fernandez M, Porosnicu M, Markovic D, Barber GN. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol. 2002;76:895–904.
   PubMed Web of Science ®Google Scholar
• Obuchi M, Fernandez M, Barber GN. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol. 2003;77:8843–8856.
   PubMed Web of Science ®Google Scholar
• Frucht DM, Fukao T, Bogdan C, Schindler H, O’Shea JJ, Koyasu S. IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol. 2001;22:556–560.
   PubMed Web of Science ®Google Scholar